Stockscreener 앱 받기
9.91
1.17%
0.12
시간 외 거래:
10.09
0.18
+1.82%
Corbus Pharmaceuticals Holdings Inc 주식(CRBP)의 최신 뉴스
Volume Surge May Signal Institutional Interest in Corbus Pharmaceuticals Holdings Inc.July 2025 Setups & Community Driven Trade Alerts - beatles.ru
Published on: 2025-08-17 09:14:34 - metal.it
Published on: 2025-08-16 20:39:17 - metal.it
Published on: 2025-08-16 18:59:42 - metal.it
Can Corbus Pharmaceuticals Holdings Inc. keep up with sector leadersJuly 2025 Macro Moves & Smart Swing Trading Alerts - thegnnews.com
Fibonacci Support Holding Strong in Corbus Pharmaceuticals Holdings Inc.Trade Volume Report & AI Driven Price Predictions - kangso.co.kr
What is the next catalyst for Corbus Pharmaceuticals Holdings Inc.Free Trading Indicator Pack - thegnnews.com
Can Cannabis Stocks Reverse Their Prolonged Downtrend? - The Globe and Mail
Oppenheimer Lowers Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $53.00 - Defense World
Corbus Pharmaceuticals Reports Q2 2025 Financials and Updates - TipRanks
William Blair Issues Negative Outlook for CRBP Earnings - Defense World
Using flow based indicators on Corbus Pharmaceuticals Holdings Inc.Free Real Time Stock Movement Analysis - Newser
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
How moving averages guide Corbus Pharmaceuticals Holdings Inc. tradingSwing Candidate List with Trade Cues - Newser
Oppenheimer Maintains Outperform Rating for CRBP with Lowered Price Target of $53.00 - AInvest
Oppenheimer Maintains Outperform Rating for CRBP, Lowers Price T - GuruFocus
Corbus Pharmaceuticals: Q2 Earnings Snapshot - New Haven Register
Corbus (CRBP) Q2 Loss Beats Estimates - AOL.com
Key metrics from Corbus Pharmaceuticals Holdings Inc.’s quarterly dataSummary of Long-Term Buy Zone Stocks - Newser
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
Corbus Pharmaceuticals Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Corbus Pharmaceuticals Receives FDA Fast Track Designation - TipRanks
Corbus Pharmaceuticals Q2 basic eps usd -1.44 - MarketScreener
Corbus Pharmaceuticals (CRBP) Gears Up for Pivotal Data Presentations in Late 2025 - GuruFocus
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | CRBP Stock News - GuruFocus
Corbus Advances 3 Clinical Programs: Obesity Drug Trial Expands, Cancer Data Coming to ESMO - Stock Titan
Is Corbus Pharmaceuticals Holdings Inc. stock overvalued or undervaluedBuild wealth steadily with smart trading - Jammu Links News
Is Corbus Pharmaceuticals Holdings Inc. a growth stock or a value stockSkyrocketing investment returns - Jammu Links News
Is Corbus Pharmaceuticals Holdings Inc. a good long term investmentFree Stock Market Return Analysis - Jammu Links News
What is the risk reward ratio of investing in Corbus Pharmaceuticals Holdings Inc. stockGet timely alerts on market opportunities - Jammu Links News
Is it the right time to buy Corbus Pharmaceuticals Holdings Inc. stockExplosive portfolio gains - Jammu Links News
What are the latest earnings results for Corbus Pharmaceuticals Holdings Inc.Superior profit margins - Jammu Links News
When is Corbus Pharmaceuticals Holdings Inc. stock expected to show significant growthDiscover breakthrough stocks before the crowd - Jammu Links News
What analysts say about Corbus Pharmaceuticals Holdings Inc. stockInvest smarter with data-backed trading alerts - Jammu Links News
What are Corbus Pharmaceuticals Holdings Inc. company’s key revenue driversFree Stock Review Backed By Experts - Jammu Links News
What is B. Riley’s Forecast for CRBP Q2 Earnings? - Defense World
What is the dividend policy of Corbus Pharmaceuticals Holdings Inc. stockFinancial News Target Finder For Smart Trading - Jammu Links News
Why is Corbus Pharmaceuticals Holdings Inc. stock attracting strong analyst attentionReal Time Tracker For Fast Growth - Jammu Links News
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Recommendation of “Buy” by Brokerages - Defense World
Corbus Pharmaceuticals stock rises after ESMO abstract acceptance By Investing.com - Investing.com Australia
Dermatomyositis Treatment Market 2034: EMA, PDMA, FDA - openPR.com
Corbus Pharmaceuticals Announces Upcoming Presentation of - GlobeNewswire
Corbus to present updated CRB-701 cancer drug data at ESMO 2025 By Investing.com - Investing.com South Africa
Corbus to present updated CRB-701 cancer drug data at ESMO 2025 - Investing.com Nigeria
Corbus Pharmaceuticals stock rises after ESMO abstract acceptance - Investing.com
CRBP: B. Riley Maintains Buy Rating with Promising Drug Potential - GuruFocus
Corbus Pharmaceuticals (CRBP) to Present Phase 1/2 Study Data at ESMO 2025 - GuruFocus
1.34%
0.52%
자본화:
|
볼륨(24시간):